Latest Breaking News On - Phase 3 reach2 study nct02913261 - Page 1 : comparemela.com

Concomitant azoles did not negatively affect efficacy with ruxolitinib or best available therapy in patients with acute graft-versus-host disease.

San antonioUnited statesZahra mahmoudjafairUniversity of kansas medical centerTrial groupCellular therapyKansas medical centerConcomitant azolesRuxolitinib treatmentAcute graft versus host diseasePost hoc analysisRandomized phaseCellular therapy meetingsTransfus cell2024 transplantation amp cellular therapy meetingsPhase 3 reach2 study nct02913261